A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study Comparing CB‐839 in Combination with Cabozantinib (CB‐Cabo) vs. Placebo with Cabozantinib (Pbo‐Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Project: OtherSponsored clinical trial

Description

A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study Comparing CB‐839 in Combination with Cabozantinib (CB‐Cabo) vs. Placebo with Cabozantinib (Pbo‐Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Short titleCX‐839‐008
AcronymMisc_Novotech
StatusActive
Effective start/end date17/07/185/06/23